A self-directed learning material to complete in your own time. With the learning module, you can learn about the unmet needs in CCA, discuss the need for molecular profiling for early patient identification and learn more about PEMAZYRE.
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to their local authority or to Incyte (by e-mail: email@example.com).
Intended for licensed healthcare professionals located in Denmark.
You are now leaving the Incyte PEMAZYRE website. This link will take you to a site that is not owned or maintained by Incyte. Incyte is not responsible for the information contained on third–party sites. Would you like to continue?